NewswireToday - /newswire/ -
Hoboken, NJ, United States, 2013/04/03 - John Wiley & Sons, Inc, announced that the majority of Wiley’s journals in its open access publishing program now offers authors funded by The Wellcome Trust and Research Councils UK the opportunity to publish their articles. NYSE: JWa, JWb
John Wiley & Sons, Inc, announced today that the majority of Wiley’s journals in its open access publishing program now offers authors funded by The Wellcome Trust and Research Councils UK the opportunity to publish their articles under a Creative Commons Attribution CC BY license when paying an Article Publication Charge (APC). This will support authors in complying with funder requirements that came into place April 1, 2013. The CC BY license allows others to modify, build upon and/or distribute the licensed work (including for commercial purposes) as long as the original author is credited.
“Enabling RCUK and Wellcome Trust funded researchers to continue publishing in the journals of their choice is very important to us,” said Rachel Burley, Vice President and Director, Open Access. “Wiley is a strong supporter of sustainable open access and is committed to meeting the needs of authors and their research funders.”
Wiley has also updated its self-archiving policy for RCUK authors. If an author funded by RCUK chooses to publish in a Wiley journal but doesn’t select and pay for OnlineOpen, they will be able to self-archive the accepted version of the article after a 12 month embargo period (starting with first publication online), or after a 24 month embargo for authors funded by the Arts and Humanities Research Council (AHRC) and the Economic and Social Research Council (ESRC). If a journal does not offer an open access option, the embargo period is reduced to 6 months (RCUK’s STM Councils) or 12 months for authors funded by AHRC and ESRC.
A limited number of society owned journals have not adopted the new self-archiving policy and/or the new OnlineOpen license policy and will continue to publish under the usual journal copyright license terms.
Wiley now publishes eighteen fully open access journals and additional journals are expected to publish in 2013. Wiley’s OnlineOpen option is offered by more than 1200 journals or more than 80% of its titles. This option is available to authors of articles who wish to make their article available to non-subscribers on publication. When selecting OnlineOpen, authors, their funding agencies, or their institutions, pay an APC to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library. Wiley Open Access Journals and those published under OnlineOpen are deposited in PubMed Central.
About Wiley Open Access
Wiley Open Access (wileyopenaccess.com) provides authors wishing to publish their research open access with a range of high quality publications which meet the requirements of funding organizations and institutions where these apply. Wiley Open Access journals are supported by a network of high-quality journals and societies as well as internationally-renowned editorial board members.
Wiley (wiley.com) is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia.